said they will discontinue a late - stage trial of
their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.
Not exact matches
The international early Phase II trial led by a team based at the Oxford
Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this
Cancer Research Centre will trial the
experimental drug called LY2181308 with advanced non-small cell
lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this
cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.
Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy trea
Cancer Research UK scientists in Oxford are trialling an
experimental drug to treat
lung cancer patients who have stopped responding to initial chemotherapy trea
cancer patients who have stopped responding to initial chemotherapy treatment.
Several other
drugs that are designed to modulate the anti-cancer immune response, such as anti-PD1 and anti-GITR, are showing promise in
experimental studies in melanoma and other
cancers, including colorectal, kidney,
lung, prostate, and ovarian
cancers and sarcoma.